·
4 minute read
The most useful question to ask a launch tracking vendor isn't about price or sample size, it's whether they can show you how promotional exposure connects to physician perception, which connects to prescribing intent, which connects to what their chart audit data shows, all from the same respondent pool, in the same data environment. Most vendors can't do this, not because they're bad at what they do, but because their research wasn't architected to connect that way.
This is a framework for evaluating any launch tracking partner against seven specific requirements, not a comparison of named vendors. Ask any candidate these seven questions and you'll learn more about what you're actually buying than a features list would tell you.
Why Most Launch Tracking Vendors Share the Same Gap
Pharma launch research vendors generally fall into one of two categories: specialist consultancies that know the industry deeply but treat market research as one service line inside a broader strategy and analytics engagement, or large generalist research firms that run rigorous survey programs across many industries but treat pharma as one vertical among several. Both categories have genuine strengths. But both tend to share the same structural gap for launch tracking specifically: awareness-trial-usage (ATU) tracking, promotional effectiveness measurement, and patient chart audits typically run as separate studies, on separately recruited physician samples, connected only after the fact at the analysis and reporting stage, not at the point of data collection.
Seven Questions to Ask Before You Sign
1. Does their research run on one unified screener? Ask whether ATU, promotional effectiveness, patient chart audit, and HCP dialogue are fielded through a single screener with genuine respondent overlap - the same physicians answering all four or as separate studies stitched together afterward. Separate studies mean synthesis happens through inference at the reporting stage, not through an actual shared respondent.
2. Do they own their physician panel? A vendor dependent on third-party panel providers has the same feasibility and scheduling lag as any outsourced recruitment process, a fast follow-up after a competitor entry or a messaging change can take weeks. A proprietary panel can typically turn one around in days.
3. Can you query live data, or only finished reports? Ask to see how you'd access your own respondents' answers the day a wave closes. A tool built for querying historical, completed research documents is a different capability than one built for real-time natural-language access to a live, in-progress dataset.
4. Is qualitative captured in the same wave, or as a separate project? Voice-first, open-ended responses embedded directly within the quantitative tracking instrument from the same respondents, at the same moment is a different research design than qualitative work commissioned as a standalone follow-up study.
5. Are their benchmarks built from launch tracking data, or borrowed from somewhere else? A launch-specific benchmark database built from actual ATU, promotional recall, and chart-audit data across comparable launches gives you a real apples-to-apples reference point. Commercial-operations or brand-equity norms adapted from other categories don't answer the same question.
6. Can they build a custom question or feature quickly? A vendor whose survey technology is licensed or partnered has to work within that platform's constraints for any new question type or logic flow. An in-house technology team can typically turn a feature request around overnight.
7. Is launch tracking their whole practice, or one service among many? A dedicated team whose entire practice is pharmaceutical launch tracking brings a different depth of institutional pattern-recognition than a team for whom your engagement is one program among dozens or hundreds.
The One Question That Cuts Through All Seven
If you only ask one thing, ask this: "Show me how promotional exposure in your research connects to physician perception, which connects to prescribing intent, which connects to what your chart audit data shows, all from the same respondent pool, in the same data environment."
A vendor built around separate studies can generally show you an analytics model that infers those connections from secondary data, or a synthesized deliverable that connects the dots after the fact across multiple reports. A vendor whose architecture connects ATU, promotional tracking, and chart audits at the point of data collection can show you the same physician's promotional recall, prescribing intent response, and chart-audit summary together, for one person, on demand.
What a Unified Architecture Looks Like in Practice
ZoomRx's own launch tracking platform is built around exactly this structure: one unified screener connecting ATU, promotional effectiveness tracking, patient chart audits, and HCP-patient dialogue in a single research architecture; a proprietary physician panel; a natural-language query tool (ZoomRx Answers) for live survey data; voice-first open-ended responses embedded in every tracking wave; and a benchmark database built from primary research on actual launches rather than adapted brand-equity norms.
For a closer look at what an integrated, archetype-level launch tracking read can surface in practice, see A Competitor Launched Six Months Before You. Is There Still Room in the Market?.
For more on the specific blind spots that cause otherwise-rigorous launch tracking programs to miss category-defining moments, ZoomRx's related whitepaper walks through five real scenarios in detail.
If you're building an RFP checklist for your next launch tracking partner, ZoomRx's Launch Excellence and ATU Brand Tracking pages walk through how this framework applies in practice.
Frequently Asked Questions
